Citations

Clear

949 citation(s) found for "Li, Bryan".

Perceived Pain is Associated with Cardiovascular Responsiveness During Metaboreflex Activation in Apparently Healthy Young Males and Females
Blumenburg, Wesley T. , Vondrasek, Joseph D. , Frederick, Josiah M., Lincoln, Zoe R., Gaither, Peter, Chall, Amy, Bryan, Anna, Grosicki, Gregory J. , Cross, Brett L. , Bock, Joshua M. , Flatt, Andrew A. , Robinson, Austin T.

Mayo Clinic

The FASEB Journal | May 3, 2022 | Volume: 36 | Issue: S1 | Pages: No page available

10.1096/fasebj.2022.36.s1.l7871 Get It

Stimuli that evoke pain stimulate the sympathetic nervous system leading to downstream vascular and hemodynamic adjustments. In clinical populations and older individuals, the perception of pain is associated with cardiovascular responses (e.g., heart rate, blood pressure, and arterial stiffness). However, there are extensive inter‐individual differences in the perception of pain, pain perception may be influenced by age, and it’s unclear if pain is associated with cardiovascular responses in younger adults. PURPOSE Therefore, we sought to determine whether heart rate, blood pressure, and arterial stiffness responses to sympathoexcitatory stimuli were associated with perceived pain, in apparently healthy young adults METHODS 17 young adults (21.6±3.9 yrs; BMI: 24.4±2.8 kg/m 2 ;Mean±SD) participated in this investigation. Following 10‐min of supine rest, we measured heart rate (HR) and mean arterial pressure (MAP), via pulse wave analysis (PWA), and arterial stiffness via carotid‐femoral pulse wave velocity (cf‐PWV). Measures were obtained in duplicate then averaged for analysis. Participants then performed a 3‐min isometric handgrip exercise (HG) at 30% of maximum voluntary contraction, which was immediately followed by 3‐min of brachial cuff‐occlusion at 240mmHg. Perceived pain was assessed via visual analog scale (0‐10; 0=no pain, 10=most pain) at the first minute of each stimulus. HR and MAP were assessed at minute two and arterial stiffness was acquired in the final minute of each stimulus. Associations between perceived pain scores during HG and cuff‐occlusion with percent change in cardiovascular responses were assessed using Spearman’s correlations (α=0.05) RESULTS During HG, significant (P<0.01) increases in HR (pre: 63±6 vs. post: 78±11 bpm; 23±15 %), MAP (pre: 86±9 vs. post: 105±14 mmHg; 22±10 %), and cf‐PWV (pre: 6.5±1.7 vs. post: 7.2±1.0 m/s; 13±26 %) were observed. During cuff‐occlusion, relative to pre, significant (P<0.05) increases in MAP (post: 100±13 mmHg; 18±15%) and cf‐PWV (post: 7.2±1.4 m/s; 14±13%), but not (P>0.05) HR (post: 64±7 bpm; 7±6%) were observed. Perceived pain during cuff‐occlusion (3.73±1.79 A.U.) was significantly greater (P=0.01) than during HG (1.88±1.20 A.U.). While no relationships were observed between perceived pain and cardiovascular responsiveness during HG (P>0.05) with HR (r=0.28; P=0.28), BP (r=0.45; P=0.07), or cf‐PVW (r=0.28; P=0.28), perceived pain was associated with increases in BP (r=0.57; P=0.02) and cf‐PWV (r=0.55; P=0.02;), but not HR (r=0.19; P=0.47), during cuff‐occlusion. CONCLUSIONS While pain during HG was not associated with cardiovascular responses, significantly greater cuff‐occlusion evoked pain was associated with cardiovascular responsiveness. Our data suggests that the relation between perceived pain and cardiovascular responsiveness to sympathoexcitatory stimuli exists in younger adults, although additional data in larger cohorts and using varied stimuli are warranted.
SARS-CoV-2 Viremia Is Associated with Lower Respiratory Tract Viral Load and Plasma Markers of Epithelial Injury and Thrombin Generation in Critically Ill Patients
Bittner, M.J., Jacobs, Jordan, Naqvi, Asma , Meyer, Michael, Methé, Barbara A. , Neal, M. , Lee, J., Morris, Alison , McVerry, Bryan J , Shah, Faraaz A , Mellors, John W , Seheult, Jansen N. , Kitsios, Georgios D , Bain, William G

Mayo Clinic

B57. CUTTING EDGE COVID RESEARCH | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3144-A3144

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3144 Get It

Association Between Submaximal Exercise Gas Exchange and Clinical Worsening Events in Patients with Pulmonary Arterial Hypertension
Call, Justin T. , Saunders, Hollie , Zeiger, Tanya, Moss, James , Burger, C.D., Taylor, Bryan J. , Helgeson, Scott A.

Mayo Clinic

B106. UNION SQUARE: OBSERVATIONAL STUDIES AND CLINICAL TRIALS IN PULMONARY HYPERTENSION | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3602-A3602

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3602 Get It

A prescription for an outpatient parenteral antimicrobial therapy ( OPAT ) rotation for pharmacy residents
Alexander, Bryan , Rivera, Christina G. , Childs‐Kean, Lindsey M. , Rivera, Christina G , Mahoney, Monica V. , Ryan, Keenan

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 2 | Pages: 234-244

10.1002/jac5.1377 Get It

Abstract Background Outpatient parenteral antimicrobial therapy (OPAT) is an emerging area for pharmacist involvement. However, many residency training programs do not offer OPAT rotation opportunities for their residents. Objective To provide a blueprint for residency programs hoping to offer OPAT rotations for postgraduate year 1 (PGY1) or postgraduate year 2 (PGY2) pharmacy residents. Results As a rotation area with copious patient interaction, there are many unique accreditation objectives that can be taught and evaluated in an OPAT rotation. The OPAT rotation format may be longitudinal or block. Activities the resident can complete include predischarge evaluation, patient counseling, medication selection, physical examinations, laboratory monitoring, patient presentations, documentation, projects, and educational presentations. Conclusion OPAT rotations provide many opportunities for residents to satisfy the objectives required in residency training.
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Hansford, Jordan R. , Huang, Jie , Endersby, Raelene , Dodgshun, Andrew , Li, Bryan , Hwang, Eugene , Gajjar, Amar , Hoff, Katja von , Wells, Olivia, Wray, Alison, Kotecha, Rishi S. , Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar‐Thomas, Arzu , Gottardo, Nicholas G. , Von Hoff, Katja , Mueller, Sabine , Schild, Steven E. , Fouladi, Maryam , Bouffet, Eric , Hansford, Jordan R , Leary, Sarah , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology Advances | April 14, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac056 | PMID 35664557 Get It

Abstract Background Pineoblastoma is a rare brain tumor usually diagnosed in children. Given its rarity, no pineoblastoma-specific trials have been conducted. Studies have included pineoblastoma accruing for other embryonal tumors over the past 30 years. These included only occasional children with pineoblastoma, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Centrally or independently reviewed series with treatment and survival data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact tests, Wilcoxon-Mann-Whitney tests, and Spearman correlations were used. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analyses. Results We describe a pooled cohort of 178 pineoblastoma cases from Children’s Oncology Group (n = 82) and institutional series (n = 96) over 30 years. Children &lt;3 years of age have significantly worse survival compared to older children, with 5-year progression-free survival (PFS) and overall survival (OS) estimates of 13.5 ± 5.1% and 16.2 ± 5.3%, respectively, compared with 60.8 ± 5.6% and 67.3 ± 5.0% for ≥3 years old (both P &lt; .0001). Multivariable analysis showed male sex was associated with worse PFS in children &lt;3 years of age (hazard ratio [HR] 3.93, 95% CI 1.80-8.55; P = .0006), suggestive of sex-specific risks needing future validation. For children ≥3 years of age, disseminated disease at diagnosis was significantly associated with an inferior 5-year PFS of 39.2 ± 9.7% (HR 2.88, 95% CI 1.52-5.45; P = .0012) and 5-year OS of 49.8 ± 9.1% (HR 2.87, 95% CI 1.49-5.53; P = .0016). Conclusion Given the rarity of this tumor, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.
Efficacy and Safety of Twice-Daily versus Three-Times Daily Saquinavir Soft Gelatin Capsules as Part of Triple Combination Therapy for HIV-1 Infection
Wheat, L. Joseph , Farthing, Charles, Cohen, Calvin, Pierone, Gerald , Lalezari, Jay , Pilson, Robert S, Siemon-Hryczyk, Peggy, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Baxter, John, Beer, Victor L., Bellos, Nicholas, Bissett, Jack, Braun, James, Brosgart, Carol, Burnside, Alfred F., Cervia, Joe, Cheeseman, Sarah H., Cimoch, Paul J., Cohen, Calvin, DeJesus, Edwin, Diaz, Leslie L, Dieterich, Douglas T. , Dobkin, Jay F., Dretler, Robin, El-Sadr, Waafa, Eng, Robert H.K., Feleke, Getachew, Fessel, Jeffrey , Fish, Douglas N. , Galpin, Jeffrey E., Gathe, Joseph, Gilson, Ian, Gold, Marla, Goodgame, Jeffrey, Greenberg, Richard N. , Greiger, Paola, Grossman, Howard, Grossman, Ron, Hanna, Barbara, Hathaway, Bruce, Hoffman-Terry, Margaret, Jacobson, Susan , Jemsek, Joseph G., Jordan, Wilbert, Kaplan, Mark, Kostman, Jay R., Landesman, Sheldon H., Lindquist, Craig, Madhava, Valsa, Marsh, Bryan J., Martin, Dean, Mathur‐Wagh, Usha, McMeeking, Alexander, Miao, Peter, Mogyoros, Miguel, Mustafa, Mahmoud M., Nadler, Jeffrey P., Norris, Dorece, Onbirbak, Brian, Parker, Richard H, Pearce, Daniel, Pierone, Gerald, Poblete, Ronald, Poretz, Donald M., Reyelt, M Christine, Rivera-Vazquez, Carlos, Salvato, Patricia, Sands, Michael, Schwartz, Robert A., Sension, Michael, Skowron, Gail, Slater, Leonard N., Stavola, Joseph, Steinhart, Corklin, Temesgen, Zelalem , Thompson, Melanie , Timpone, Joseph, Vollmer, Kelly, Wada, Suzanne, Wheat, L Joseph, Yangco, Bienvenido G., Carey, Peter, Jablonowski, H, Theisen, Albert, Ocana, Inma, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Burman, William J. , Cohen, Calvin, Feinberg, Judith , Goodrich, James , Jacobson, Susan, Kaplan, Mark, Lalezari, Jacob , MacArthur, Rodger D. , Murphy, Robert L. , Mustafa, Mahmoud, Pierone, Gerald, Reyelt, M. Christine, Smith, David C. , Valentine, Fred T. , Ward, Douglas, Wheat, L Joseph, Carey, Peter, Lazzarin, Adriano , Ocana, Inma

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 7 | Issue: 3 | Pages: 199-209

10.1177/135965350200700310 Get It

Objective The objective of this study was to determine whether a triple therapy regimen incorporating twice-daily saquinavir is as effective as a three-times daily regimen. Methods This was an open-label, Phase III, multicentre, 48-week study involving 837 HIV-1-infected patients randomised to one of the following: saquinavir soft gel capsule (SGC) 1200 mg three-times daily, plus two nucleoside reverse transcriptase inhibitors (NRTIs) (arm A); saquinavir SGC 1600 mg twice-daily, plus two NRTIs (arm B); saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily, plus a single NRTI (arm C). The primary outcome measure was the virological response in arm A versus B and in arm A versus C with respect to the percentage of patients whose plasma HIV-1 RNA levels fell below the level of quantification for the Amplicor assay (<400 copies/ml) at weeks 24 and 48. Results At 48 weeks, the percentage of patients with plasma HIV-1 RNA levels <400 copies/ml was 47.1% (arm A), 45.3% (arm B) and 42.7% (arm C) in the intention-to-treat analysis. The treatment difference between arm B–arm A was -1.8% (95% confidence intervals -10.1, 6.5) and for arm C–arm A was -4.5% (95% confidence intervals -12.7, 3.7) in the intention-to-treat analysis. These differences fell within the maximum allowable difference (±12%) for arm B compared with arm A. At week 24, the percentage of patients with HIV-1 RNA levels <400 copies/ml was 59.6% (arm A), 57.6% (arm B) and 51.3% (arm C). Conclusions A twice-daily triple therapy regimen incorporating saquinavir SGC plus two NRTIs was of equivalent efficacy to the three-times daily regimen studied. All regimens were generally well tolerated.
Exploring the role of expectancy in older US participants’ response to an accelerated resolution therapy intervention for prolonged grief disorder
Buck, Harleah G. , Benitez, Bryan , Tofthagen, Cindy , Tofthagen, Cindy S , Mason, Tina M. , Hernandez, Diego, Mogle, Jacqueline A.

Mayo Clinic

Health & Social Care in the Community | April 9, 2022 | Volume: 30 | Issue: 6 | Pages: No page available

10.1111/hsc.13813 | PMID 35396879 Get It

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Achufusi, Amaka, Armand, Philippe , Bhatia, Shailender , Chokshi, Saurin , Davies, Marianne, Elshoury, Amro, Gesthalter, Yaron , Kaffenberger, Benjamin H. , Li, Tianhong , Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Oluwole, Olalekan O. , Patel, Sandip Pravin , Patil, Pradnya D. , Reddy, Sunil , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Lyons, Megan , Dwyer, Mary A., Hang, Lisa, Oluwole, Olalekan O , Kaffenberger, B , Ryder, Mabel , Berkenstock, Meghan , Budde, Lihua E. , Hegde, Aparna , Jain, Michael D. , Lechner, Melissa G , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 387-405

10.6004/jnccn.2022.0020 | PMID 35390769 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Sauer, Bryan G. , Wani, Sachin , Falk, Gary W. , Yadlapati, Rena

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4 | Pages: 559-587

10.14309/ajg.0000000000001680 | PMID 35354777 Get It

Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.